Dec 7 (Reuters) - Euroapi Sas EAPI.PA :
* EUROAPI UPDATES ITS 2022 FINANCIAL GUIDANCE
* EUROAPI NOW ANTICIPATES NET SALES REACHING CIRCA EUR 980
MILLION
AND A CORE EBITDA MARGIN BETWEEN 12% - 13% IN 2022
* TEMPORARY AND PROACTIVE SUSPENSION OF PROSTAGLANDIN
PRODUCTION
ACTIVITIES AT BUDAPEST SITE FOLLOWING A ROUTINE INTERNAL
ASSESSMENT
* GROUP IDENTIFIED SOME GOOD MANUFACTURING PRACTICES
DEFICIENCIES
RELATED TO DOCUMENTATION MANAGEMENT
* GROUP ANTICIPATES NET SALES CIRCA EUR 980 MILLION AND A
CORE
EBITDA MARGIN BETWEEN 12% - 13% IN 2022, DUE TO LOSS OF SALES,
RELATED PROVISIONS, AND REMEDIATION COSTS
* THIS TEMPORARY AND TARGETED PAUSE OF PRODUCTION WILL
AFFECT
EUROAPI'S BUSINESS ACTIVITIES AND FINANCIAL PERFORMANCE
* GROUP ESTIMATES THAT PROSTAGLANDIN PRODUCTION COULD REMAIN
SUSPENDED FOR A FEW WEEKS
Source text for Eikon: ID:nBw2Bpm14a
Further company coverage: EAPI.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))